Direkt zum Inhalt
Merck

IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis.

JCI insight (2018-08-24)
Amy C Gross, Hakan Cam, Doris A Phelps, Amanda J Saraf, Hemant K Bid, Maren Cam, Cheryl A London, Sarah A Winget, Michael A Arnold, Laura Brandolini, Xiaokui Mo, John M Hinckley, Peter J Houghton, Ryan D Roberts
ZUSAMMENFASSUNG

Osteosarcoma (OS), a malignant tumor of bone, kills through aggressive metastatic spread almost exclusively to the lung. Mechanisms driving this tropism for lung tissue remain unknown, though likely invoke specific interactions between tumor cells and other cells within the lung metastatic niche. Aberrant overexpression of ΔNp63 in OS cells directly drives production of IL-6 and CXCL8. All these factors were expressed at higher levels in OS lung metastases than in matched primary tumors from the same patients. Expression in cell lines correlated strongly with lung colonization efficiency in murine xenograft models. Lentivirus-mediated expression endowed poorly metastatic OS cells with increased metastatic capacity. Disruption of IL-6 and CXCL8 signaling using genetic or pharmaceutical inhibitors had minimal effects on tumor cell proliferation in vitro or in vivo, but combination treatment inhibited metastasis across multiple models of metastatic OS. Strong interactions occurred between OS cells and both primary bronchial epithelial cells and bronchial smooth muscle cells that drove feed-forward amplification of IL-6 and CXCL8 production. These results identify IL-6 and CXCL8 as primary mediators of OS lung tropism and suggest pleiotropic, redundant mechanisms by which they might effect metastasis. Combination therapy studies demonstrate proof of concept for targeting these tumor-lung interactions to affect metastatic disease.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
SC144 hydrochloride, ≥98% (HPLC)
Avanti
Lactosyl(β) Sphingosine (d18:1), Avanti Research - A Croda Brand 860542P, powder